Project Grant R01AG089349
Award Date
5/15/25
Completion Date
2/28/30
Dollars Obligated
$488K
Federal Agency
National Institute on Aging
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
Charlestown, MA 02129, USA
Similar Awards
This Project Grant award from the National Institute on Aging's Aging Research Federal Grant Program (CFDA 93.866) provides $452,550 to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to investigate the role of glial fibrillary acidic protein (GFAP) upregulation in reactive astrocytes and its impact on tripartite excitatory synapses in a tauopathy mouse model of Alzheimer's disease. The research aims to delineate changes in the protein composition and...
The National Institutes of Health's National Institute on Aging awarded a $5,063,226 Project Grant to Brigham and Women's Hospital Inc. under the Aging Research program (CFDA 93.866) for the period of September 1, 2022 through August 31, 2025. The grant funds research to analyze the functional role of glial cells in tauopathy and Alzheimer's disease. Researchers will use genetic approaches in Drosophila to identify glial proteins and pathways that influence tau neurotoxicity in aging adult fly...
This $1,611,000 federal Project Grant awarded by the National Institute on Aging (CFDA 93.866 - Aging Research) to Brigham & Women's Hospital Inc. aims to illuminate the role of somatic mutations in the development of primary tauopathies, a group of neurodegenerative diseases including Alzheimer's. The project will leverage single-cell whole-genome sequencing of human brain tissue to examine somatic mutations in neurons and glia, as well as utilize cellular models to dissect mechanisms...
This federal Project Grant award of $1,118,700.00 from the National Institute on Aging (CFDA 93.866 - Aging Research) to New York University School of Medicine will support research to elucidate the role of pathological tau protein in disrupting endosomal microautophagy (EMI), a critical protein degradation pathway affected in Alzheimer's disease. The research aims to determine which components of the EMI pathway are most vulnerable to tau pathology and whether restoring EMI function can...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) to The Johns Hopkins University provides $146,922 to investigate physiological pathways modulating tau homeostasis, with potential implications for Alzheimer's disease and related dementias. The primary research objectives are to: Examine how the loss of the glycerophosphodiester phosphodiesterase 2 (GDE2) protein affects the onset and progression of neurodegeneration, tau modifications, and...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $459,250 to The General Hospital Corporation (dba Massachusetts General Hospital) to investigate the impact of stress and resilience on the progression of Alzheimer's disease pathology and cognitive function. The 2-year project aims to leverage longitudinal data from established research cohorts to determine the temporal associations between stress, resilience, amyloid and tau pathology,...
This federal Project Grant award of $816,661 from the National Institute on Aging (CFDA 93.866 - Aging Research) supports a research initiative by the Regents of the University of California, San Francisco (UCSF) to comprehensively map the impact of tau pathology on the proteome, which is expected to be mediated in part through disruptions in mRNA splicing. The research leverages AD mouse models and human iPSC tauopathy models to discover protein drivers of tauopathy and validate such drivers in...
This Project Grant award from the National Institute on Aging's Aging Research Federal Grant Program (CFDA 93.866) provides $2,173,794.00 to The General Hospital Corporation (Massachusetts General Hospital) to conduct research aimed at developing strategies to enhance adult hippocampal neurogenesis (AHN) and brain-derived neurotrophic factor (BDNF) as a potential therapeutic approach for treating cognitive decline in Alzheimer's disease (AD). The research project seeks to: 1) explore the...
This federal Project Grant award of $2,895,962 from the National Institute on Aging's Aging Research program (CFDA 93.866) supports research to investigate how a microRNA, miR-129-2, may protect against tau accumulation and neurodegeneration in Alzheimer's disease. The project, conducted by Trustees of Boston University, aims to map the expression of miR-129-2 in the entorhinal cortex across mouse and human samples, examine how miR-129-2 regulates Alzheimer's disease-relevant genes and pathways,...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $157,568 to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to study the conjoint effects of dopamine and tau on cognition in aging. The proposed research will leverage neuroimaging techniques, including simultaneous MR/PET, to examine how endogenous dopamine release and tau pathology interact to impact reward memory in older adults. Specific aims...